Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oNKo-038
- Development stage
- Preclinical
- Lead developer
- oNKo-innate
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
oNKo-038 is a preclinical CAR-NK cell therapy being developed by oNKo-innate for the treatment of cancer, specifically neoplasms. It represents an intracellular checkpoint target in orthogonal cytokine pathways, identified through CRISPR screening of primary human NK cells. The drug involves novel genetic edits designed to enhance the fitness and anti-tumor function of CAR-NK cells, particularly under conditions of repetitive antigen stimulation and immunosuppression. When paired with another candidate (oNKo-046), these edits have shown to significantly improve CAR-NK cell function[1][2][3].
- Other names
- oNKo 038oNKo038oNKo-038
Beyond the preview
Go deeper on oNKo-038.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oNKo-038.